# Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults

> **NCT00387738** · PHASE2 · TERMINATED · sponsor: **Dynavax Technologies Corporation** · enrollment: 738 (actual)

## Conditions studied

- Rhinitis, Allergic, Seasonal

## Interventions

- **BIOLOGICAL:** Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate
- **BIOLOGICAL:** Histamine base

## Key facts

- **NCT ID:** NCT00387738
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** 2007-05
- **Final completion:** 2008-03
- **Target enrollment:** 738 (ACTUAL)
- **Why stopped:** Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect.
- **Last updated:** 2019-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387738, "Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00387738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*